{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T07:43:55Z","timestamp":1772437435886,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bpgastro.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.bpg.2012.12.004","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T14:01:29Z","timestamp":1365602489000},"page":"803-818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours"],"prefix":"10.1016","volume":"26","author":[{"given":"Anders","family":"Sundin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2012.12.004_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CCO.0b013e3282f1c595","article-title":"Neuroendocrine tumors of the diffuse neuroendocrine system","volume":"20","author":"Gustafsson","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.bpg.2012.12.004_bib2","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.12.004_bib3","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bpg.2012.12.004_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.beem.2006.12.003","article-title":"Nuclear imaging of neuroendocrine tumours","volume":"21","author":"Sundin","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.bpg.2012.12.004_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000184855","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations","volume":"90","author":"Sundin","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.bpg.2012.12.004_bib6","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bpg.2012.12.004_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ecl.2010.12.003","article-title":"Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Kwekkeboom","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.bpg.2012.12.004_bib8","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00261-003-0162-3","article-title":"Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS","volume":"29","author":"Kumbasar","year":"2004","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.bpg.2012.12.004_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1148\/radiology.206.1.9423664","article-title":"Carcinoid metastases to the liver: role of triple-phase helical CT","volume":"206","author":"Paulson","year":"1998","journal-title":"Radiology"},{"key":"10.1016\/j.bpg.2012.12.004_bib10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2214\/ajr.181.3.1810775","article-title":"Preoperative detection of pancreatic insulinomas on multiphasic helical CT","volume":"181","author":"Fidler","year":"2003","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.bpg.2012.12.004_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2005.01.013","article-title":"Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging","volume":"23","author":"Dromain","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bpg.2012.12.004_bib12","first-page":"58","article-title":"Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET\/CT and PET\/MRI","volume":"11","author":"Seemann","year":"2006","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.bpg.2012.12.004_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/SLA.0b013e3181bdf8cf","article-title":"Hepatic metastases from neuroendocrine tumors with a \u201cthin slice\u201d pathological examination: they are many more than you think\u2026","volume":"251","author":"Elias","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.bpg.2012.12.004_bib14","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1016\/j.ejrad.2011.11.007","article-title":"Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI","volume":"81","author":"Giesel","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.bpg.2012.12.004_bib15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jmri.1182","article-title":"MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver","volume":"14","author":"Bader","year":"2001","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.bpg.2012.12.004_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2214\/ajr.180.1.1800121","article-title":"MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques","volume":"180","author":"Dromain","year":"2003","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.bpg.2012.12.004_bib17","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1007\/s00330-010-1840-5","article-title":"Endocrine pancreatic tumours: which are the most useful MRI sequences?","volume":"20","author":"Caramella","year":"2010","journal-title":"Eur Radiol"},{"key":"10.1016\/j.bpg.2012.12.004_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1148\/radiol.2241010798","article-title":"Prospective evaluation of pancreatic tumors: accuracy of MR imaging with MR cholangiopancreatography and MR angiography","volume":"224","author":"Lopez H\u00e4nninen","year":"2002","journal-title":"Radiology"},{"key":"10.1016\/j.bpg.2012.12.004_bib19","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000176207","article-title":"Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI","volume":"89","author":"Rockall","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.bpg.2012.12.004_bib20","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1007\/s10620-008-0570-x","article-title":"Detection of hepatic metastases from carcinoid tumor: prospective evaluation of contrast-enhanced ultrasonography","volume":"54","author":"Hoeffel","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpg.2012.12.004_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.dld.2010.01.009","article-title":"Contrast-enhanced ultrasonography in evaluating hepatic metastases from neuroendocrine tumours","volume":"42","author":"Massironi","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.bpg.2012.12.004_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0929-8266(99)00054-3","article-title":"Endosonography in decision-making and management of gastrointestinal endocrine tumors","volume":"10","author":"De Angelis","year":"1999","journal-title":"Eur J Ultrasound"},{"key":"10.1016\/j.bpg.2012.12.004_bib23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.gie.2009.12.023","article-title":"Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors","volume":"71","author":"Ishikawa","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.bpg.2012.12.004_bib24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.gie.2010.08.030","article-title":"EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors","volume":"73","author":"Khashab","year":"2011","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.bpg.2012.12.004_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/RLU.0b013e3181d6677c","article-title":"Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study","volume":"35","author":"Versari","year":"2010","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.bpg.2012.12.004_bib26","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10620-011-1912-7","article-title":"EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience","volume":"57","author":"Atiq","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpg.2012.12.004_bib27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.gie.2009.12.006","article-title":"EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience","volume":"71","author":"Pais","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.bpg.2012.12.004_bib28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000225946","article-title":"ENETS Consensus Guidelines for\u00a0the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide","volume":"90","author":"Kwekkeboom","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"Suppl. 11","key":"10.1016\/j.bpg.2012.12.004_bib29","first-page":"132","article-title":"Neuroendocrine tumors and somatostatin: imaging techniques","volume":"28","author":"de Herder","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.bpg.2012.12.004_bib30","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.ejrad.2010.07.022","article-title":"PET\/CT with 68Gallium-DOTA-peptides in NET: an overview","volume":"80","author":"Ambrosini","year":"2011","journal-title":"Eur J Radiol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.12.004_bib31","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1007\/s00259-011-1989-4","article-title":"68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET","volume":"39","author":"Ambrosini","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2012.12.004_bib32","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","article-title":"68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors","volume":"52","author":"Poeppel","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2012.12.004_bib33","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s00259-011-1760-x","article-title":"68Ga-DOTATOC PET\/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax","volume":"38","author":"Boy","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2012.12.004_bib34","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00259-011-1846-5","article-title":"Molecular imaging with 68Ga-SSTR PET\/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours","volume":"38","author":"Kaemmerer","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2012.12.004_bib35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00259-008-0944-5","article-title":"Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET\/CT","volume":"36","author":"Miederer","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2012.12.004_bib36","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"68 Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT","volume":"48","author":"Gabriel","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2012.12.004_bib37","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","article-title":"Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (OctreoScan) SPECT in patients with neuroendocrine tumours","volume":"34","author":"Buchmann","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2012.12.004_bib38","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2967\/jnumed.109.066134","article-title":"The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy","volume":"51","author":"Srirajaskanthan","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2012.12.004_bib39","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","article-title":"The impact of 68Ga-DOTATOC positron emission tomography\/computed tomography on the multimodal management of patients with neuroendocrine tumors","volume":"252","author":"Frilling","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.bpg.2012.12.004_bib40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1754-9485.2011.02327.x","article-title":"High management impact of Ga-68 DOTATATE (GaTate) PET\/CT for imaging neuroendocrine and other somatostatin expressing tumours","volume":"56","author":"Hofman","year":"2012","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.bpg.2012.12.004_bib41","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.109.071712","article-title":"68Ga-DOTANOC PET\/CT clinical impact in patients with neuroendocrine tumors","volume":"51","author":"Ambrosini","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2012.12.004_bib42","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1007\/s00330-011-2199-y","article-title":"Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours","volume":"21","author":"Kumar","year":"2011","journal-title":"Eur Radiol"},{"key":"10.1016\/j.bpg.2012.12.004_bib43","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2214\/AJR.11.7298","article-title":"Gallium-68-DOTA-NOC PET\/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study","volume":"197","author":"Naswa","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.bpg.2012.12.004_bib44","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11307-010-0374-1","article-title":"68Ga-DOTA-NOC PET\/CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-octreotide (OctreoScan)","volume":"13","author":"Krausz","year":"2011","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.bpg.2012.12.004_bib45","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00259-008-0769-2","article-title":"Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours","volume":"35","author":"Ambrosini","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2012.12.004_bib46","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00259-008-1030-8","article-title":"Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours","volume":"36","author":"Haug","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2012.12.004_bib47","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.1998.16.7.2534","article-title":"Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors","volume":"16","author":"Orlefors","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bpg.2012.12.004_bib48","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1210\/jc.2004-1938","article-title":"Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography","volume":"90","author":"Orlefors","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpg.2012.12.004_bib49","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2007.15.1126","article-title":"Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography","volume":"26","author":"Koopmans","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bpg.2012.12.004_bib50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002590050197","article-title":"Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours","volume":"25","author":"Adams","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bpg.2012.12.004_bib51","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/cncr.23469","article-title":"Functional imaging of neuroendocrine tumors with combined PET\/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG","volume":"112","author":"Kayani","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bpg.2012.12.004_bib52","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2967\/jnumed.109.066639","article-title":"A comparison of 68Ga-DOTATATE and 18F-FDG PET\/CT in pulmonary neuroendocrine tumors","volume":"50","author":"Kayani","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2012.12.004_bib53","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.109.069765","article-title":"Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET","volume":"51","author":"Binderup","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2012.12.004_bib54","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2967\/jnumed.108.057505","article-title":"Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors","volume":"50","author":"Garin","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2012.12.004_bib55","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","article-title":"18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors","volume":"16","author":"Binderup","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bpg.2012.12.004_bib56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3892\/ol_00000029","article-title":"Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to the World Health Organization classification","volume":"1","author":"Masui","year":"2010","journal-title":"Oncol Lett"},{"key":"10.1016\/j.bpg.2012.12.004_bib57","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2214\/AJR.09.2760","article-title":"Value of CT enteroclysis in suspected small-bowel carcinoid tumors","volume":"194","author":"Kamaoui","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.bpg.2012.12.004_bib58","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/j.1572-0241.2006.00749.x","article-title":"Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience","volume":"101","author":"Bailey","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2012.12.004_bib59","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1007\/s10620-011-1773-0","article-title":"CT-enterography may identify small bowel tumors not detected by capsule endoscopy: eight years experience at Mayo Clinic Rochester","volume":"56","author":"Hakim","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpg.2012.12.004_bib60","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2214\/ajr.164.2.7839976","article-title":"Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation","volume":"164","author":"Pantongrag-Brown","year":"1995","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.bpg.2012.12.004_bib61","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1111\/j.1572-0241.2000.02480.x","article-title":"Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas","volume":"95","author":"Anderson","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2012.12.004_bib62","first-page":"584","article-title":"Contrast-enhanced ultrasound in the diagnosis of pancreatic tumors","volume":"7","author":"Rickes","year":"2006","journal-title":"JOP"},{"key":"10.1016\/j.bpg.2012.12.004_bib63","doi-asserted-by":"crossref","first-page":"W472","DOI":"10.2214\/AJR.05.0809","article-title":"MRI of islet cell tumors of the pancreas","volume":"187","author":"Herwick","year":"2006","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.bpg.2012.12.004_bib64","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1245\/s10434-012-2305-7","article-title":"Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis","volume":"19","author":"Poultsides","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bpg.2012.12.004_bib65","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/jmri.22541","article-title":"Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics","volume":"33","author":"Wang","year":"2011","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.bpg.2012.12.004_bib66","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.ejrad.2011.09.012","article-title":"Fluid-fluid level in hepatic metastases: a characteristic sign of metastases of neuroendocrine origin","volume":"81","author":"Sommer","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.bpg.2012.12.004_bib67","doi-asserted-by":"crossref","unstructured":"McDermott S, O'Neill AC, Skehan SJ. Staging of gastroenteropancreatic neuroendocrine tumors: how we do it based on an evidence-based approach. Clin Imaging, in press.","DOI":"10.1016\/j.clinimag.2012.05.006"},{"key":"10.1016\/j.bpg.2012.12.004_bib68","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1148\/radiol.09090021","article-title":"Diffusion-weighted MR imaging of the liver","volume":"254","author":"Taouli","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.bpg.2012.12.004_bib69","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1016\/j.ejrad.2012.01.032","article-title":"Pancreatic neuroendocrine tumor: added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection","volume":"81","author":"Brenner","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.bpg.2012.12.004_bib70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2214\/AJR.07.2550","article-title":"Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization","volume":"190","author":"Liapi","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.bpg.2012.12.004_bib71","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000342270","article-title":"Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead","volume":"96","author":"Sundin","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.bpg.2012.12.004_bib72","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2967\/jnumed.108.053421","article-title":"68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy","volume":"50","author":"Gabriel","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2012.12.004_bib73","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2967\/jnumed.110.075002","article-title":"68Ga-DOTATATE PET\/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors","volume":"51","author":"Haug","year":"2010","journal-title":"J Nucl Med"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691813000309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691813000309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T09:50:12Z","timestamp":1562925012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691813000309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1521691813000309"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2012.12.004","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2012.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}